Dear manager, The INSPIRE clinical trial 1 examining necitumumab in non-squamous lung cancer was a negative study. In the squamous subtype —a recently approved indication. The SQUIRE 2 study, which compares cisplatin plus gemcitabine plus or minus necitumumab...
© 2001-2026 Fundación Dialnet · Todos los derechos reservados